A live Q&A was held on Tuesday, May 4, 2010, to discuss the approval of the prostate cancer vaccine, Provenge, which has recently been approved by the US Food and Drug Administration (FDA). Provenge was created by Dendreon, a biotech firm located in Seattle.

The session was conducted by Sandi Doughton, science reporter of Seattle Times, Dr. Celestia Higano, Professor at the University of Washington School of Medicine, and David Miller, CEO, Biotech Stock Research.

Dr. Higano is a leading prostate cancer specialist and is also a member of Seattle Cancer Care Alliance. She has been involved in the clinical trials of Provenge.

David Miller is also covering and as an independent analyst has been covering Dendreon for the last nine years.

Dr. Higano did her M. D. from the University of Massachusetts. She is also a member of the Fred Hutchinson Cancer Research Center. Dr. Higano started to build a team of doctors in 1995 which is known as the Prostate Cancer Clinical Research Program. The emphasis of her research is on prostate cancer and the impact of androgen deprivation on men with non-metastatic disease, novel targeted therapies, chemotherapy, and immunotherapy.

David Miller is a renowned expert in the field of biotech investing. He is also the CEO of Biotech Stock Research. He is also a technical analyst and an expert commentator on the market. He has been covering the activities and progress of Dendreon for the last nine years. Miller had predicted that the sale of Provenge may be around $1 billion in coming two to three years.